European CHMP recommends license extension of ixekizumab (Taltz)

The license extension is for the treatment of moderate to severe plaque psoriasis in children from the age of 6 years and with a body weight of at least 25 kg and adolescents who are candidates for systemic therapy.


European Medicines Agency